Serum Tests for Diagnosis and Follow-Up of Hepatocellular Carcinoma after Treatment

Publisher Website
Google Scholar
Abstract
Hepatocellular carcinoma (HCC) is a well-established complication of liver cirrhosis with an annual incidence of 2–7% [1]. Since patients with HCC are prone to develop recurrent and second liver tumors after potentially curative therapy, it is mandatory to screen these patients using several diagnostic methods, including ultrasonographyand appropriate serological tumor markers. In the past years, a variety of new tumor markersother than α-fetoprotein have been proposed for diagnosis and follow-up of HCC.